CARLSBAD, CALIFORNIA–(Marketwired – Jan 25, 2017) – Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSX VENTURE:ASG) announced the appointment of Sarina Mason as their Chief Financial Officer (CFO), effective February 6, 2017.
Ms. Mason will help guide and oversee the company’s continued market leadership and financial growth. She brings more 16 years of experience to Aurora Spine.
Prior to joining Aurora Spine, Ms. Mason was Director of Accounting & Finance at International Stem Cell Corp., a publically traded company.
Ms. Mason began her career with Ernst and Young working primarily in the Assurance and Advisory Business Services group. Ms. Mason earned a Bachelor of Science in Accounting from San Diego State University.
Former CFO Eric Fronk has resigned from the Company effective February 6, 2017 to pursue other opportunities.
“We are very pleased to have someone with Sarina’s skills and experience join Aurora Spine,” said Trent J. Northcutt, President and CEO of Aurora Spine. “Sarina has a wealth of expertise in financial management as well as proven leadership capabilities that will be a great asset as we capitalize on the opportunities that lie ahead of us.” He added, “I would like to thank outgoing CFO Eric Fronk for his substantial contributions to the Company.”
About Aurora Spine
Aurora Spine is an early stage company focused on bringing new solutions to the spinal implant market through a series of screwless, innovative, minimally invasive, regenerative spinal implant technologies. Aurora Spine continues to position itself at the forefront of spinal surgery procedures, focusing on minimally invasive spine surgery technologies. Aurora Spine is changing spine surgery by focusing on disruptive technologies following the Company’s commitment to – Simplifying the Complex.
Forward-Looking Statements
This news release contains forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurora Spine, including, without limitation, those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Information” in Aurora Spine’s final prospectus (collectively, “forward-looking information”). Forward-looking information in this news release includes information concerning the proposed use and success of the company’s products in surgical procedures. Aurora Spine cautions investors of Aurora Spine’s securities about important factors that could cause Aurora Spine’s actual results to differ materially from those projected in any forward-looking statements included in this news release. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ unilaterally from those expressed in such forward-looking statements. No assurance can be given that the expectations set out herein will prove to be correct and, accordingly, prospective investors should not place undue reliance on these forward looking statements. These statements speak only as of the date of this press release and Aurora Spine does not assume any obligation to update or revise them to reflect new events or circumstances.
